Jubilant Pharmova Ltd Company History

Enters the Bio / chemo informatics arena by setting up Jubilant Biosys Ltd.

New corporate identity: Jubilant Organosys Ltd. reflecting changed corporate and business profile

Acquires the Active Pharmaceutical Ingredients business

Trading symbol of Jubilant Organosys Limited is changed from 'VAMORGANIC ' to 'JUBILANT'

Jubliant Securites Pvt. Ltd. & Jubliant Capital Pvt. Ltd has acquired 4,38,068 (2.99% of total paid up capital) equity shares.

Mr. H K Khan (Retd. IAS) has been appointed as additional director with effect from November 05, 2003 on the Board.

Jubilant Organosys Limited has informed that the Board of Directors at their meeting held on January 9, 2004 have approved for voluntary delisting of equity shares of the Company from The Delhi Stock Exchange Association Limited, The Calcutta Stock Exchange Association Limited, Kolkata and the Uttar Pradesh Stock Exchange Association Limited subject to the approval of shareholders by special resolution.

Jubilant Organosys acquires generic pharma Companies in Europe

Jubilant Organosys signs international contracts worth US$ 60 million in CRAMS for the year 2007

Acquired pharmaceutical company in USA involved in off patent drug development and supply, and owns US FDA approved manufacturing facility for solid dosage forms.

Acquires full service Clinical Research Organization in USA involved in providing clinical research services, data management, biostatistics and contract staffing.

Acquires Target Research Associates, Inc., renamed Clinsys Inc.; a US based Clinical Research Organisation (CRO)

Acquires Trinity Laboratories, Inc. and its wholly owned subsidiary, Trigen Laboratories, Inc., renamed Jubilant Pharmaceuticals, Inc., a generic pharmaceutical company in USA having a US FDA approved formulations manufacturing facility

Enters Clinsys Clinical Research Ltd. business by setting up wholly owned subsidiary Jubilant Clinsys Ltd.

Selected as one of the top 25 companies for Institute of Company Secretaries of India National Award for Excellence in Corporate Governance

Finalist in Golden Peacock Award for Excellence in Corporate Governance

Company has splits its Face value of Shares from Rs 5 to Re 1

Jubilant Organosys Ltd has acquired 100% equity stake in Hollister-Stier Laboratories LLC, USA, engaged in high growth Injectable contract manufacturing and well established and stable Allergy Immunotherapy businesses.

Acquires Hollister Stier Laboratories in USA, a contract manufacturer of Sterile injectable vials and allergenic extracts.

Acquires DRAXIS Specialty Pharmaceuticals, Inc. Canada, a contract manufacturer of sterile & non-sterile products and radiopharmaceuticals

Acquires Speciality Molecules Pvt. Ltd. Engaged in the manufacturing of Fine Chemicals used by Life Science Industry including pharma, agro & cosmetic industry.

Jubilant Organosys and Lilly form Drug development joint venture

Uttar Pradesh-based pharma major Jubilant Organosys Ltd (JOL) has secured new contracts worth $92 million (Rs.3.7 billion). The contracts have been signed under Customs Research and Manufacturing Services (CRAMS). Besides marketing its products in the regulated markets of the US, Europe and Japan, the company has managed to make forays into China, said a statement of JOL.

Jubilant enters into multiple Drug discovery partnerships with leading pharma and biotech -companies such as AstraZeneca, Orion, Endo pharmaceuticals & BioLeap and also extends its collaboration with Lilly for five years.

Jubilant enters into drug development collaborations with academia, University of Alabama at Birmingham and Southern Research Institute (USA) and Duke University (Singapore).

Jubilant Kalpataru – 120 bed super specialty hospital at Barasat, Kolkata, India inaugurated by Hon’ble Minister of Finance Shri Pranab Mukherjee

ET – IMEA 2009 Platinum Award by Frost & Sullivan, in the Pharmaceutical category for the API facility at Nanjangud

Best CFO (FMCG, Health and Retail Sector) to Mr. R. Sankaraiah by Institute of Chartered Accountants of India in January, 2010

Jubilant Organosys Ltd has appointed Mr. Shardul S. Shroff as Additional Director of the Company with effect from March 15, 2010.

Jubilant Organosys Ltd has signed a USD 51 million CRAMS contract with a leading Life Sciences Company

The Company has changed from "Jubilant Organosys Ltd" to "JUBILANT LIFE SCIENCES LTD"

Mr. Shardul S. Shroff has been appointed as Additional Director of the Company.

Jubilant Life Sciences Ltd has announced another successful delivery of an early stage milestone in the Pain therapeutic area.

Jubilant Org - Jubilant sets up global scale capacities for Symtet - developed through

JubilantLife - announced today that they have achieved an early stage milestone in one of their collaborative programs with Chadds Ford.

"Jubilant HollisterStier Announces Multi-Million Dollar Award for the manufacture of Sterile Parenteral Products".

"Jubilant SEZ at Bharuch, inaugurated by Shri Narendra Modi, Hon’ble Chief Minister of Gujarat".

"Jubilant Life Sciences receives prestigious NDTV Profit Business Leadership Award 2012 for Corporate Social Responsibility."

Jubilant Life Sciences receives ANDA approval for Quetiapine Fumarate Tablet

Jubilant Life Sciences declared winner of Supply Chain Excellence Awards’ at 7th Express, Logistics & Supply Chain Leadership Awards 2013

Jubilant Life Scienc - Results of Tender Offer for acquisition of minority shares of Cadista Holdings Inc.

Board recommended a Dividend of Rs.3 per equity shares of Rs.1

Jubilant Life Sciences wins Excellence Awards at ‘India Pharma Awards’ 2014

Jubilant Life Sciences conferred with Golden Peacock Business Excellence Award-2014

Gold Award in Ankleshwar Chapter Convention on Quality Concepts 2015 (ACCQC)

Two Honors at the 10th Annual CIO100 Awards by CIO Magazine - CIO100 Innovation Architect Special Awards 2015 and Versatile 100honorees

Golden Peacock National Quality Award for Quality

Dataquest Business Technology Awards for Best IT Implementation in Analytics, Mobility, Cloud, ERP/CSM/CRM

ASSOCHAM’s ‘Responsible Organization Excellence’ Award 2014-15

50 Most Talented Sustainability Leaders Award

15th Annual Greentech Environment Award 2014 - Gold Category winner under Chemicals and Pharmaceutical sector” - Gajraula plant, India

I.C.O.N.I.C IDC Insights Award, under ‘Health and Life Sciences vertical

Jubilant Life Sciences Limited won the Sustainability Award for Best Green Process in Chemical sector of FICCI Chemicals & Petrochemicals Awards, 2016.

Jubilant gets USFDA nod for generic anti-fungal capsules.

Jubilant Life eyes speciality pharma biz acquisition in US.

Jubilant completes acquisition of Radiopharmacy business of Triad.

"Second Awards" under the category of Basic Inorganic, Organic Chemicals including Agro Chemicals for the outstanding export performance of the year 2015-16 by CHEMEXCIL.

'Most Consistent IR (Investor Relations) Practice in the country' Award for the year 2017 instituted by IR Society of India

Green tech Environment Award 2017 received by Nanjangud Plant Jubilant Life Sciences Ltd, Gajraula awarded with CII 17th National

Award for Excellence in Energy Award 2016 In Category of Chemical/Pharma/Fertilizers.

Jubilant Life Sciences setting up a greenfield pesticide manufacturing unit at Bharuch

Jubilant Life gets green nod for Rs 250-cr pesticide project

Jubilant Life Sciences agreement to acquire 10 per cent stake in Inipharm Inc USA

Announcing the finalists of Social Entrepreneur of the Year (SEOY) India 2018 Award

Jubilant receives ANDA approval for Niacin Extended-Release Tablets USP

Jubilant Life Sciences celebrating a decade of partnership ‘Social Entrepreneur of the Year India Awards’

Jubilant Life Sciences supports distribution of health and safety material in Karnataka to manage COVID-19 crisis

Jubilant Life Sciences gives free hand sanitizers to support fight against COVID-19

Schwab Foundation for Social Entrepreneurship & Jubilant Bhartia Foundation Presents the Hindustan Times Fellowship that delivers the Seed Transformation Program in India.

Jubilant Life Sciences Limited announces launch of ‘JUBI-R’ (remdesivir) in India for the treatment of COVID-19

Company name has changed to Jubilant Pharmova Ltd. from Jubilant Life Sciences Ltd..

Jubilant Pharmova Limited is undertaking of Jubilant Generics Limited

Jubilant HollisterStier announces CAD 100 Mn expansion of its CMO manufacturing facility at Montreal, Canada.

Jubilant HollisterStier LLC enters into cooperative agreement of $149.6 Mn with US Government to expand critical vaccine manufacturing capacity.

Jubilant to Present Data on Isoform Selective PAD4 inhibitors in the Treatment of Cancer at the American Association of Cancer Research Annual (AACR) Meeting 2022

Jubilant Announces FDA Clearance of IND for JBI-802, a Novel Dual LSD1 and HDAC6 Inhibitor, for treatment of Solid Tumors.

Jubilant received additional funding from Govt. of Canada for expansion of Montreal facility.

Jubilant's Radiopharma biz got USFDA approval for Technetium Mertiatide injection.